Akorn, Inc.
1925 West Field Court
Lake Forest
Illinois
60045
United States
Tel: 847-279-6100
Fax: 847-236-3823
Website: http://www.akorn.com/
248 articles with Akorn, Inc.
-
Akorn secured approval for a post-operative eye drop, as well as a generic over-the-counter version of GSK's Flonase.
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline - AKRX
4/10/2019
Pomerantz LLP announces that a class action lawsuit has been filed against Akorn, Inc. and certain of its officers and directors.
-
BioSpace Movers and Shakers: March 22
3/22/2019
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more. -
The FDA issues Warning Letters to biopharma, medical device and food companies when they find that a manufacturer has significantly violated FDA regulations. As of March 4, the agency issued 45 Warning Letters this year.
-
Allergan indicated that it “has shifted [its] priority from expanding the Waco site to investing significantly in our existing operations.” However, the company spokesperson said that Allergan “remains committed to our eye care business and operations in Waco.”
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
Akorn Comments on Delaware Chancery Court Ruling
10/1/2018
Akorn, Inc. (NASDAQ:AKRX), today issued a statement in response to the ruling by the Delaware Chancery Court on the complaint filed by Akorn against Fresenius Kabi AG
-
Despite positive Phase III clinical trial data for Allergan’s age-related macular degeneration drug, investors weren’t as positive about it.
-
Almost one year to the day after Fresenius plunked down $4.3 billion to acquire Illinois-based Akorn Pharmaceuticals, the German company announced it was walking away from the deal.
-
Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations under Merger Agreement
4/23/2018
Akorn, Inc. (NASDAQ:AKRX), today filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement, and issued the following statement:
-
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
-
AKORN, INC. INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Akorn, Inc.
3/21/2018
The law firm Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the publicly traded securities of Akorn, Inc. between March 1, 2017 and February 26, 2018.
-
Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday.
-
Akorn Shareholders Vote To Approve Merger Agreement With Fresenius Kabi AG
7/20/2017
-
U.S. Generic Drugmaker Akorn Surges On Reports Fresenius SE Is Interested
4/10/2017
-
Akorn, Inc. Receives FDA Approval For Ephedrine Sulfate Injection, USP
3/2/2017
-
Akorn, Inc. Receives Approval For Mycophenolate Mofetil For Injection, USP
3/1/2017
-
Akorn, Inc. Provides Fourth Quarter And Full Year 2016 Results And Outlines Full Year 2017 Guidance
3/1/2017
-
Akorn, Inc. To Report Fourth Quarter And Full Year 2016 Results
2/6/2017
-
Akorn, Inc. Announces Completion Of FDA Re-Inspection Of Decatur Facility
12/12/2016